CBS 2019
CBSMD教育中心
中 文

急性冠脉综合征

Abstract

Recommended Article

Association Between Collateral Circulation and Myocardial Viability Evaluated by Cardiac Magnetic Resonance Imaging in Patients With Coronary Artery Chronic Total Occlusion Cardiac Troponin Composition Characterization after Non ST-Elevation Myocardial Infarction: Relation with Culprit Artery, Ischemic Time Window, and Severity of Injury A randomised trial comparing two stent sizing strategies in coronary bifurcation treatment with bioresorbable vascular scaffolds - The Absorb Bifurcation Coronary (ABC) trial Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial Coronary CT Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement Early versus delayed invasive intervention in acute coronary syndromes Decreased inspired oxygen stimulates de novo formation of coronary collaterals in adult heart

Original ResearchVolume 74, Issue 3, July 2019

JOURNAL:J Am Coll Cardiol. Article Link

Myocardial Infarction Risk Stratification With a Single Measurement of High-Sensitivity Troponin I

Y Sandoval, R Nowak, CR deFilippi et al. Keywords: acute myocardial infarction; high-sensitivity cardiac troponin; risk stratification; troponin

ABSTRACT


BACKGROUND- Limited data exist on rapid risk-stratification strategies using the U.S. Food and Drug Administrationcleared high-sensitivity cardiac troponin I (hs-cTnI) assays.

 

OBJECTIVES- This study sought to examine single measurement hs-cTnI to identify patients at low and high risk for acute myocardial infarction (MI).

 

METHODS- This was a prospective, multicenter, observational study of patients with suspected acute MI enrolled across 29 U.S. sites with hs-cTnI measured using the Atellica IM TnIH and ADVIA Centaur TNIH (Siemens Healthineers) assays. To identify low-risk patients, sensitivities and negative predictive values (NPVs) for acute MI and MI or death at 30 days were examined across baseline hs-cTnI concentrations. To identify high-risk patients, positive predictive values and specificities for acute MI were evaluated.

 

RESULTS- Among 2,212 patients, acute MI occurred in 12%. The limits of detection or quantitation resulted in excellent sensitivities (range 98.6% to 99.6%) and NPVs (range 99.5% to 99.8%) for acute MI or death at 30 days across both assays. An optimized threshold of <5 ng/l identified almost one-half of all patients as low risk, with sensitivities of 98.6% (95% confidence interval: 97.2% to 100%) and NPVs of 99.6% (95% confidence interval: 99.2% to 99.9%) for acute MI or death at 30 days across both assays. For high-risk patients, hs-cTnI 120 ng/l resulted in positive predictive values for acute MI of 70%.

 

CONCLUSIONS- Recognizing the continuous relationship between baseline hs-cTnI and risk for adverse events, using 2 Food and Drug Administrationcleared hs-cTnI assays, an optimized threshold of <5 ng/l safely identified almost one-half of all patients as low risk at presentation, with hs-cTnI 120 ng/l identifying high-risk patients.